We found that the numbers of CCR7+ and CCR7+ICOS+ memory Tfh cells in MS patients after treatment were significantly lower than that in those patients before treatment, but remained significantly higher than that in the HC (Fig 2A, 2B and 2E). This evidence concerns the gene CCR7 and myeloid sarcoma.